Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).

Spreafico A, Oza AM, Clarke BA, Mackay HJ, Shaw P, Butler M, Dhani NC, Lheureux S, Wilson MK, Welch S, Zhang T, Yu C, Stockley T, Siu LL, Kamel-Reid S, Bedard PL.

Gynecol Oncol. 2017 Feb;144(2):250-255. doi: 10.1016/j.ygyno.2016.12.002. Epub 2017 Jan 3.

PMID:
28062115
2.

TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.

Rechsteiner M, Zimmermann AK, Wild PJ, Caduff R, von Teichman A, Fink D, Moch H, Noske A.

Exp Mol Pathol. 2013 Oct;95(2):235-41. doi: 10.1016/j.yexmp.2013.08.004. Epub 2013 Aug 18.

PMID:
23965232
3.

Molecular diagnosis in type I epithelial ovarian cancer.

Sadłecki P, Walentowicz-Sadłecka M, Grabiec M.

Ginekol Pol. 2017;88(12):692-697. doi: 10.5603/GP.a2017.0123. Review.

4.

Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.

Despierre E, Yesilyurt BT, Lambrechts S, Johnson N, Verheijen R, van der Burg M, Casado A, Rustin G, Berns E, Leunen K, Amant F, Moerman P, Lambrechts D, Vergote I; EORTC GCG and EORTC GCG Translational Research Group.

Int J Gynecol Cancer. 2014 Mar;24(3):468-77. doi: 10.1097/IGC.0000000000000089.

PMID:
24557434
5.

Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.

Mackenzie R, Kommoss S, Winterhoff BJ, Kipp BR, Garcia JJ, Voss J, Halling K, Karnezis A, Senz J, Yang W, Prigge ES, Reuschenbach M, Doeberitz MV, Gilks BC, Huntsman DG, Bakkum-Gamez J, McAlpine JN, Anglesio MS.

BMC Cancer. 2015 May 19;15:415. doi: 10.1186/s12885-015-1421-8.

6.

Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.

Tone AA, McConechy MK, Yang W, Ding J, Yip S, Kong E, Wong KK, Gershenson DM, Mackay H, Shah S, Gilks B, Tinker AV, Clarke B, McAlpine JN, Huntsman D.

BMC Cancer. 2014 Dec 18;14:982. doi: 10.1186/1471-2407-14-982.

7.

Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer.

Takahashi N, Yamada Y, Taniguchi H, Fukahori M, Sasaki Y, Shoji H, Honma Y, Iwasa S, Takashima A, Kato K, Hamaguchi T, Shimada Y.

BMC Res Notes. 2014 Apr 29;7:271. doi: 10.1186/1756-0500-7-271.

8.

Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.

Jauhri M, Bhatnagar A, Gupta S, Bp M, Minhas S, Shokeen Y, Aggarwal S.

Tumour Biol. 2017 Feb;39(2):1010428317692265. doi: 10.1177/1010428317692265.

PMID:
28222664
9.

Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.

Della Pepa C, Tonini G, Santini D, Losito S, Pisano C, Di Napoli M, Cecere SC, Gargiulo P, Pignata S.

Cancer Treat Rev. 2015 Feb;41(2):136-43. doi: 10.1016/j.ctrv.2014.12.003. Epub 2014 Dec 23. Review.

PMID:
25573350
10.

PIK3CA mutations in advanced cancers: characteristics and outcomes.

Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R.

Oncotarget. 2012 Dec;3(12):1566-75.

11.

PIK3CA alterations in Middle Eastern ovarian cancers.

Abubaker J, Bavi P, Al-Haqawi W, Jehan Z, Munkarah A, Uddin S, Al-Kuraya KS.

Mol Cancer. 2009 Jul 28;8:51. doi: 10.1186/1476-4598-8-51.

12.

Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.

Nodin B, Zendehrokh N, Sundström M, Jirström K.

Diagn Pathol. 2013 Jun 25;8:106. doi: 10.1186/1746-1596-8-106.

13.

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.

Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M.

Acta Oncol. 2014 Jul;53(7):852-64. doi: 10.3109/0284186X.2014.895036. Epub 2014 Mar 25. Review.

PMID:
24666267
14.

Analysis and comparison of somatic mutations in paired primary and recurrent epithelial ovarian cancer samples.

Kim YM, Lee SW, Chun SM, Kim DY, Kim JH, Kim KR, Kim YT, Nam JH, van Hummelen P, MacConaill LE, Hahn WC, Jang SJ.

PLoS One. 2014 Jun 17;9(6):e99451. doi: 10.1371/journal.pone.0099451. eCollection 2014.

15.

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.

Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R.

PLoS One. 2011;6(7):e22769. doi: 10.1371/journal.pone.0022769. Epub 2011 Jul 29.

16.

A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.

Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB.

Oncogene. 2012 Oct 18;31(42):4559-66. doi: 10.1038/onc.2011.539. Epub 2011 Dec 5.

17.

Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.

Dienstmann R, Serpico D, Rodon J, Saura C, Macarulla T, Elez E, Alsina M, Capdevila J, Perez-Garcia J, Sánchez-Ollé G, Aura C, Prudkin L, Landolfi S, Hernández-Losa J, Vivancos A, Tabernero J.

Mol Cancer Ther. 2012 Sep;11(9):2062-71. doi: 10.1158/1535-7163.MCT-12-0290. Epub 2012 Jun 21.

18.

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.

Kawazoe A, Shitara K, Fukuoka S, Kuboki Y, Bando H, Okamoto W, Kojima T, Fuse N, Yamanaka T, Doi T, Ohtsu A, Yoshino T.

BMC Cancer. 2015 Apr 11;15:258. doi: 10.1186/s12885-015-1276-z.

19.

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21.

PMID:
23429431
20.

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.

Grisham RN, Sylvester BE, Won H, McDermott G, DeLair D, Ramirez R, Yao Z, Shen R, Dao F, Bogomolniy F, Makker V, Sala E, Soumerai TE, Hyman DM, Socci ND, Viale A, Gershenson DM, Farley J, Levine DA, Rosen N, Berger MF, Spriggs DR, Aghajanian CA, Solit DB, Iyer G.

J Clin Oncol. 2015 Dec 1;33(34):4099-105. doi: 10.1200/JCO.2015.62.4726. Epub 2015 Aug 31.

Supplemental Content

Support Center